Loading clinical trials...

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma | Clinical Trials | Clareo Health

COMPLETEDPHASE2

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

A Multicentre, Phase II, Open Label, Single Arm Study of Pixantrone in Patients With CD20-positive Relapsed or Refractory Aggressive Non-Hodgkin Lymphoma Treated With Rituximab, Ifosfamide and Etoposide.

NCT03458260•The Lymphoma Academic Research Organisation

View on ClinicalTrials.gov

Summary

This study will evaluate the efficacy of Pixantrone with rituximab, ifosfamide and etoposide as measured by the overall metabolic response rate after 2 cycles of treatment or at permanent treatment discontinuation.

Detailed Description

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•1. Histologically proven CD20+ aggressive non-Hodgkin lymphoma (diffuse large B-cell lymphoma (DLBCL), de novo or transformed DLBCL from previously untreated low grade non-Hodgkin lymphoma or grade 3b follicular lymphoma) as per the World Health Organization (WHO) 2016 criteria
•2. Relapsed or refractory disease, defined as follows:

Exclusion Criteria

•2. Or patients in first relapse after Autologous Stem Cell Transplant (ASCT)
•3. Age \> or =18 years
•4. Eastern Cooperative Oncology Group (ECOG) performance status \< or = 2
•5. Subjects must have evaluable disease based on positron emission tomography (PET-CT) scan
•6. Minimum life expectancy of 6 months
•7. Signed written informed consent
•8. Patient covered by any social security system
•9. Men must agree to use a barrier method of contraception during the treatment period and until 6 months after the last dose of chemotherapy
•10. Women of childbearing potential must agree to use an adequate method of contraception, such as oral contraceptives, intrauterine device, or barrier method of contraception during the treatment period and until 12 months after the last dose of chemotherapy
•1. Any other histological type of lymphoma (Burkitt lymphoma, mantle-cell lymphoma…)
+32 more criteria

Locations (22)

AZ Sint Jan

Bruges, Belgium

Institut Jules Bordet - Centre des tumeurs de l'ULB

Brussels, Belgium

Centre Hospitalier de Jolimont

Haine-Saint-Paul, Belgium

CH d'Avignon

Avignon, France

Centre Hospitalier de la Côte Basque

Bayonne, France

CHU Jean Minjoz

Besançon, France

Hôpital Haut-Lévèque

Bordeaux, France

Centre Hospitalier William Morey

Chalon-sur-Saône, France

Clinique Victor Hugo

Le Mans, France

CHRU de Lille

Lille, France

Key Dates

Start Date

December 26, 2018

Primary Completion Date

December 24, 2024

Completion Date

December 24, 2024

Last Updated

March 10, 2026

Enrollment

ACTUAL participants

Conditions

Aggressive Non-Hodgkin Lymphoma

Interventions

Pixantrone

DRUG

Ifosfamide

OTHER

Etoposide

OTHER

Rituximab

OTHER

Transplant

PROCEDURE

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

NCT03749018

Aggressive Non-Hodgkin LymphomaAnn Arbor Stage I Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma+12 more

View study

ACTIVE_NOT_RECRUITINGNA

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

NCT01787409

Aggressive Non-Hodgkin LymphomaAnaplastic Large Cell Lymphoma+13 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 10, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Inclusion Criteria

Exclusion Criteria

Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Cholecalciferol in Improving Survival in Patients With Newly Diagnosed Cancer With Vitamin D Insufficiency

Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma

Nivolumab and Combination Chemotherapy in Treating Participants With Diffuse Large B-Cell Lymphoma

Metronomic Chemotherapy in Elderly Non-fit Patients With Aggressive B-Cell Lymphomas

Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer